Body dysmorphic disorder Mental and Behavioural Disorders Body dysmorphic disorder
Conditions
Interventions
Randomization.
Following diagnosis and baseline assessment, participants who meet eligibility criteria will be randomly allocated to one of two treatment modalities at point of entry into the study us
2) level of depression as assessed by the BDI, 3) participant preferences and 4) clinician judgement. For all patients
Sponsors
Centre de recherche de l'Institut universitaire en santé mentale de Montréal
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Age >18 years 2. A primary diagnosis of BDD according to DSM-5 criteria 3. No change in medication during the 12 weeks before treatment for antidepressants (4 weeks for anxiolytics) 4. Willingness to keep medication stable while participating in the study (g) not undergoing a current psychological treatment 5. Willingness to undergo active psychological treatment 6. Willingness to undergo randomization into treatment modality 7. Fluency in French
Exclusion criteria
Exclusion criteria: 1. Evidence of suicidal intent 2. Evidence of current substance abuse 3. Past or present psychotic or bipolar disorder 4. Neurocognitive, developmental disorder or intellectual disability
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BDD symptoms assessed using the Yale-Brown Obsessive-Compulsive Scale Modified for BDD (BDD-YBOCS) at pre and post-treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. BDD symptoms assessed pre and post-treatment by self-report with the Body Dysmorphic Symptom Scale (BDD-SS) 2. Overvalued ideation - Level of OVI will be assessed pre and post-treatment with the Over-Valued Ideas Scale (OVIS) 3. Anxiety will be assessed pre and post-treatment with The Beck Anxiety Inventory (BAI) 4. Depression will be assessed pre and post-treatment with the Beck Depression Inventory (BDI) 5. Obsessive beliefs will be measured at pre- and post-treatment with the 20-item version of the Obsessive Beliefs Questionnaire (OBQ-TRIP) 6. Level of inferential confusion will be formally assessed at pre-treatment, post-treatment and follow-up by the validated Inferential Confusion Questionnaire — Expanded Version (ICQ-EV) 7. Feared self-perceptions will be assessed pre- and post-treatment with the expanded version of the Fear of Self Questionnaire (FSQ-Expanded Version). 8. Dissociative Absorption will be assessed pre and post-treatment with an adapted version of the Selves Questionnaire 9. Obsessive-compulsive symptoms will be assessed pre and post-treatment with the Vancouver Obsessive-Compulsive Inventory (VOCI) 10. Dissociation will be assessed pre and post-treatment with the Dissociative Processes Scale (DPS) 11. Disability and impairment in work, social life and family responsibilities will be measured pre and post-treatment with the Sheehan Disability Scale (SDS) 12. Quality of life will be assessed pre and post-treatment with the Brunsviken Brief Quality of Life Scale 13. Social self-esteem will be assessed pre and post-treatment with the Social Self-Esteem Inventory (STI) 14. Global self-esteem will be assessed pre and post-treatment with the Rosenberg’s Self-Esteem Scale (RSES) 15. Self-report measures to measure treatment acceptability and satisfaction will be administered immediately following the 1st, 8th and 16th treatment session: 15.1 Distress/Endorsement Validation Scale (DEVS) 15.2 The Treatment Acceptability/Adherence Scale (TAAS) 15.3 | — |
Countries
Canada
Outcome results
None listed